These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38221889)

  • 41. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
    Jiang W; Zhu D; Wang C; Zhu Y
    Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors.
    Li H; Lv Z; Liu M
    Medicine (Baltimore); 2023 Oct; 102(41):e35196. PubMed ID: 37832111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Yu L; Ji T; Liao W; Xu Y; Fang Y; Zhu Q; Nie J; Yang D
    Clin Epigenetics; 2023 Mar; 15(1):43. PubMed ID: 36932439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
    Li BL; Wan XP
    J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Remodeling the bladder tumor immune microenvironment by mycobacterial species with changes in their cell envelope composition.
    Senserrich J; Guallar-Garrido S; Gomez-Mora E; Urrea V; Clotet B; Julián E; Cabrera C
    Front Immunol; 2022; 13():993401. PubMed ID: 36304456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.
    Song Q; Zhou R; Shu F; Fu W
    Front Immunol; 2022; 13():958368. PubMed ID: 35990642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
    Song Q; Zhou Z; Bai J; Liu N
    Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer.
    Chen X; Chen H; Yao H; Zhao K; Zhang Y; He D; Zhu Y; Cheng Y; Liu R; Xu R; Cao K
    Oncogene; 2021 Nov; 40(45):6381-6393. PubMed ID: 34588621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High ORAI3 expression correlates with good prognosis in human muscle-invasive bladder cancer.
    Yan J; Yu W; Lu C; Liu C; Wang G; Jiang L; Jiang Z; Qin Z
    Gene; 2022 Jan; 808():145994. PubMed ID: 34626722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune cell deconvolution of bulk DNA methylation data reveals an association with methylation class, key somatic alterations, and cell state in glial/glioneuronal tumors.
    Singh O; Pratt D; Aldape K
    Acta Neuropathol Commun; 2021 Sep; 9(1):148. PubMed ID: 34496929
    [TBL] [Abstract][Full Text] [Related]  

  • 51. m1A Regulatory gene signatures are associated with certain immune cell compositions of the tumor microenvironment and predict survival in kidney renal clear cell carcinoma.
    Zhou L; Zhou W; Li Y; Hua R
    Eur J Med Res; 2023 Sep; 28(1):321. PubMed ID: 37679761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
    Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
    J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.
    Chen H; Zhang T; Zhang Y; Wu H; Fang Z; Liu Y; Chen Y; Wang Z; Jia S; Ji X; Shang L; Du F; Liu J; Lu M; Chong W
    JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35511432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers.
    Koestler DC; Marsit CJ; Christensen BC; Accomando W; Langevin SM; Houseman EA; Nelson HH; Karagas MR; Wiencke JK; Kelsey KT
    Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1293-302. PubMed ID: 22714737
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
    Zhang X; Liu H; Zhang J; Wang Z; Yang S; Liu D; Liu J; Li Y; Fu X; Zhang X
    Arch Esp Urol; 2023 Feb; 76(1):70-83. PubMed ID: 36914422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
    Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
    Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
    Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
    BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
    Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
    Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.